This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Astatine is a chemical element; it has symbol At and atomic number 85. It is the rarest naturally occurring element in the Earth's crust, occurring only as the decay product of various heavier elements. All of astatine's isotopes are short-lived; the most stable is astatine-210, with a half-life of 8.1 hours. Consequently, a solid sample of the element has never been seen, because any macroscopic specimen would be immediately vaporized by the heat of its radioactivity. The bulk properties of astatine are not known with certainty. Many of them have been estimated from its position on the periodic table as a heavier analog of fluorine, chlorine, bromine, and iodine, the four stable halogens. However, astatine also falls roughly along the dividing line between metals and nonmetals, and some metallic behavior has also been observed and predicted for it. Astatine is likely to have a dark or lustrous appearance and may be a semiconductor or possibly a metal. Chemically, several anionic species of astatine are known and most of its compounds resemble those of iodine, but it also sometimes displays metallic characteristics and shows some similarities to silver. The first synthesis of astatine was in 1940 by Dale R. Corson, Kenneth Ross MacKenzie, and Emilio G. Segrè at the University of California, Berkeley. They named it from the Ancient Greek ástatos (ἄστατος) 'unstable'. Four isotopes of astatine were subsequently found to be naturally occurring, although much less than one gram is present at any given time in the Earth's crust.
== Behavior informatics == Behavior informatics, also called behavior computing, explores behavior intelligence and behavior insights from the informatics and computing perspectives. Different from applied behavior analysis from the psychological perspective, behavior informatics builds computational theories, systems and tools to qualitatively and quantitatively model, represent, analyze, and manage behaviors of individuals, groups and/or organizations.
Aniceto Lacson, November 5, 1898 – July 22, 1899 (to November 27, 1898, in Negros Occidental) Demetrio Larena, November 24, 1898 – November 27, 1898 (in Negros Oriental) President of the Constituent Assembly José Luzuriaga, July 22, 1899 – November 6, 1899 Secretary of War Juan Araneta Civil Governor Melecio Severino, November 6, 1899 – April 30, 1901 Secretary of Justice Antonio Ledesma Jayme, November 5, 1898 – July 22, 1899
== Secondary metabolite == Prodigiosin is a secondary metabolite of Serratia marcescens. Because it is easy to detect, it has been used as a model system to study secondary metabolism. Prodigiosin production has long been known to be enhanced by phosphate limitation. In low phosphate conditions, pigmented strains have been shown to grow to a higher density than unpigmented strains.
Sources: en.wikipedia.org
This is a list of scandals or controversies whose names include a -gate suffix, by analogy with the Watergate scandal in the 1970s, as well as other incidents to which the suffix has (often facetiously) been applied. This list also includes controversies that are widely referred to with a -gate suffix, but may be referred to by another more common name (such as the New Orleans Saints bounty scandal, known as "Bountygate"). Use of the -gate suffix has spread beyond American English to many other countries and languages.
Benzo[a]pyrene is first oxidized by cytochrome P450 1A1 to form a variety of products, including (+)-benzo[a]pyrene-7,8-epoxide. This product is metabolized by epoxide hydrolase, opening up the epoxide ring to yield (−)-benzo[a]pyrene-7,8-dihydrodiol. The ultimate carcinogen is formed after another reaction with cytochrome P450 1A1 to yield the (+)-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide. It is this diol epoxide that covalently binds to DNA. BaP induces cytochrome P450 1A1 (CYP1A1) by binding to the AHR (aryl hydrocarbon receptor) in the cytosol. Upon binding the transformed receptor translocates to the nucleus where it dimerises with ARNT (aryl hydrocarbon receptor nuclear translocator) and then binds xenobiotic response elements (XREs) in DNA located upstream of certain genes. This process increases transcription of certain genes, notably CYP1A1, followed by increased CYP1A1 protein production. This process is similar to induction of CYP1A1 by certain polychlorinated biphenyls and dioxins. Seemingly, CYP1A1 activity in the intestinal mucosa prevents major amounts of ingested benzo[a]pyrene to enter portal blood and systemic circulation. Intestinal, but not hepatic, expression of CYP1A1 depends on TOLL-like receptor 2 (TLR2), which is a eukaryotic receptor for bacterial surface structures such as lipoteichoic acid. Moreover, BaP has been found to activate a transposon, LINE1, in humans.
gene mapping Any of a variety of methods used to precisely identify the location of a particular gene within a DNA molecule (such as a chromosome) and/or the physical or linkage distances between it and other genes.
Aromatic L-amino acid decarboxylase deficiency, also known as AADC deficiency, is a rare genetic disorder caused by mutations in the DDC gene, which encodes an enzyme called aromatic L-amino acid decarboxylase.
== Doubts about existence == In October 2011 the Journal of Strategic Studies, a leading journal in that field, published an article by Thomas Rid, "Cyber War Will Not Take Place" which argued that all politically motivated cyber attacks are merely sophisticated versions of sabotage, espionage, or subversion – and that it is unlikely that cyber war will occur in the future.
Sources: en.wikipedia.org
Jennifer Moyle (1921-2016), British biochemist involved in the development of the chemiosmosic theory Kary Mullis (1944–2019). American biochemist at the Cetus Corporation (Emeryville, California), inventor of the polymerase chain reaction. Nobel Prize in Chemistry (1993).
== Applications == Ranganathan and Lockless originally developed SCA to examine thermodynamic (energetic) coupling of residue pairs in proteins. Using the PDZ domain family, they were able to identify a small network of residues that were energetically coupled to a binding site residue. The network consisted of both residues spatially close to the binding site in the tertiary fold, called contact pairs, and more distant residues that participate in longer-range energetic interactions. Later applications of SCA by the Ranganathan group on the GPCR, serine protease and hemoglobin families also showed energetic coupling in sparse networks of residues that cooperate in allosteric communication. Statistical coupling analysis has also been used as a basis for computational protein design. In 2005, Socolich et al. used an SCA for the WW domain to create artificial proteins with similar thermodynamic stability and structure to natural WW domains. The fact that 12 out of the 43 designed proteins with the same SCA profile as natural WW domains properly folded provided strong evidence that little information—only coupling information—was required for specifying the protein fold. This support for the SCA hypothesis was made more compelling considering that a) the successfully folded proteins had only 36% average sequence identity to natural WW folds, and b) none of the artificial proteins designed without coupling information folded properly.
This competition could alter the post-transcriptional gene regulation (PTGR) of ADME-related genes, leading to indirect modulation of the expression of drug-metabolizing enzymes or transporters and causing DDIs with co-administered drugs. Short hairpin RNAs (shRNAs) may additionally compete with pre-miRNAs for the nuclear export protein Exportin-5 (XPO5) and the cytoplasmic ribonuclease Dicer, disrupting global miRNA biogenesis and posing further DDI risk. The U.S. Food and Drug Administration has issued guidance specific to oligonucleotide therapeutics, recommending assessment of QTc interval prolongation, immunogenicity, organ-impairment effects on PD endpoints, and the potential for RNAi machinery competition as part of the DDI risk framework for this drug class.
== Research == The best known CCK receptor antagonist is the non-selective antagonist proglumide, which blocks both CCKA and CCKB receptors, and was originally developed for the treatment of stomach ulcers. This action derived from its blockade of CCKA receptor in the gut and consequent reduction in secretion of gastric acid, however a side effect of proglumide was found, namely that it increases the analgesic effects of opioid painkillers, and decreases the development of tolerance. This was subsequently found to result from its blockade of CCKB receptors in the brain. Another CCK receptor antagonist is benzotript, which is likewise non-selective. Newer drugs have since been developed which are selective for one or other of the CCK receptors. Selective CCKA receptor antagonists such as lorglumide and devazepide have been developed both for their anti-ulcer effects and as potential drugs to limit the development of gastrointestinal cancers such as colon cancer. A centrally selective antagonist—Ranquilon—has recently undergone clinical approval for the treatment of anxiety in Russia. The main focus of CCK receptor antagonist research has focused on the development of selective CCKB receptor antagonists as novel medications which have been primarily investigated for the treatment of anxiety and panic attacks, as well as for other roles such as analgesic effects.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.